Last reviewed · How we verify
Misoprostol 25mcg
At a glance
| Generic name | Misoprostol 25mcg |
|---|---|
| Also known as | Prostokos Cytotec |
| Sponsor | Professor Fernando Figueira Integral Medicine Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Induction of Labour at Term With Low Dose Oral Misoprostol Versus a Foley Catheter (PHASE4)
- A Randomized Trial of Oral Misoprostol Alone Versus Oral Misoprostol Followed by Oxytocin for Labour Induction (PHASE4)
- Comparison of Misoprostol Ripening Efficacy With Dilapan (PHASE4)
- Misoprostol Versus Oxytocin for Induction of Labour in Parturients With Spontaneous Rupture of Fetal Membranes at Term (NA)
- Labor Protocol Study
- Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions (NA)
- qMOLI- A Qualitative Assessment of Misoprostol or Oxytocin for Labour Induction
- Cervical Ripening in Premature Rupture of Membranes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Misoprostol 25mcg CI brief — competitive landscape report
- Misoprostol 25mcg updates RSS · CI watch RSS
- Professor Fernando Figueira Integral Medicine Institute portfolio CI